Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition
E Ramacciotti, JI Weitz - Thrombosis Research, 2019 - Elsevier
This review provides the rationale for dual pathway inhibition with the combination of low-
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
E Ramacciotti, JI Weitz - Thrombosis Research, 2019 - europepmc.org
This review provides the rationale for dual pathway inhibition with the combination of low-
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition
E Ramacciotti, JI Weitz - Thrombosis research, 2019 - pubmed.ncbi.nlm.nih.gov
This review provides the rationale for dual pathway inhibition with the combination of low-
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition
E Ramacciotti, JI Weitz - Thrombosis Research, 2019 - thrombosisresearch.com
This review provides the rationale for dual pathway inhibition with the combination of low-
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …
dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg …